• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Rescue use of Pegylated Interferon in Dialysis Patient who Failed to Respond Sofosbuvir.聚乙二醇化干扰素在对索磷布韦无反应的透析患者中的挽救性应用。
Indian J Nephrol. 2023 Mar-Apr;33(2):152-154. doi: 10.4103/ijn.IJN_259_21. Epub 2023 Feb 20.
2
Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review.索磷布韦、利巴韦林和聚乙二醇干扰素治疗对达卡他韦耐药的3型丙型肝炎病毒：病例报告及文献复习
Rev Inst Med Trop Sao Paulo. 2019 Feb 14;61:e12. doi: 10.1590/S1678-9946201961012.
3
FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin.
Gastroenterology. 2014 Dec;147(6):1196-200. doi: 10.1053/j.gastro.2014.10.027. Epub 2014 Oct 27.
4
Sofosbuvir for the treatment of chronic hepatitis C virus infection.索磷布韦用于治疗慢性丙型肝炎病毒感染。
Drugs Today (Barc). 2014 Jun;50(6):421-34. doi: 10.1358/dot.2014.50.6.2141371.
5
Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.三名患者在肝移植后接受索磷布韦加来迪帕司韦治疗复发性丙型肝炎。
Clin J Gastroenterol. 2017 Apr;10(2):179-184. doi: 10.1007/s12328-017-0722-7. Epub 2017 Feb 21.
6
Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.索磷布韦、聚乙二醇干扰素和利巴韦林在埃及丙型肝炎病毒感染人群真实临床实践中的治疗应用
Infect Disord Drug Targets. 2019;19(2):179-184. doi: 10.2174/1871526518666180912121835.
7
Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.在意大利，索磷布韦联合利巴韦林加或不加聚乙二醇干扰素治疗慢性丙型肝炎的成本效益
J Med Econ. 2015;18(9):678-90. doi: 10.3111/13696998.2015.1040024. Epub 2015 Jun 5.
8
Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.聚乙二醇化干扰素（单独使用或与利巴韦林联用）用于血液透析人群的慢性丙型肝炎治疗。
Kidney Blood Press Res. 2015;40(3):258-65. doi: 10.1159/000368501. Epub 2015 May 14.
9
Management of hepatitis C virus infection in the Asia-Pacific region: an update.亚太地区丙型肝炎病毒感染的管理：更新。
Lancet Gastroenterol Hepatol. 2017 Jan;2(1):52-62. doi: 10.1016/S2468-1253(16)30080-2. Epub 2016 Dec 10.
10
Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation.肾肝联合移植术后应用聚乙二醇干扰素、利巴韦林和索磷布韦成功治疗纤维化胆汁淤积性肝炎。
Transpl Int. 2015 Feb;28(2):255-8. doi: 10.1111/tri.12428. Epub 2014 Sep 29.

引用本文的文献

1
Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India.索磷布韦/维帕他韦/伏西瑞韦用于难治性患者丙型肝炎病毒再治疗：来自印度的一项真实世界观察性研究
J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101314. doi: 10.1016/j.jceh.2023.101314. Epub 2023 Dec 9.

本文引用的文献

1
INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease.国际肝脏研究协会（INASL）与国际肾脏病学会（ISN）关于肝肾同时患病患者管理的联合立场声明
J Clin Exp Hepatol. 2021 May-Jun;11(3):354-386. doi: 10.1016/j.jceh.2020.09.005. Epub 2020 Oct 9.
2
Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.使用8周泛基因型达卡他韦和减量索磷布韦治疗晚期肾衰竭患者的急性丙型肝炎
Nephrol Dial Transplant. 2021 Sep 27;36(10):1867-1871. doi: 10.1093/ndt/gfaa187.
3
Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation.索磷布韦-维帕他韦固定剂量复方用于治疗终末期肾病和肾移植患者的慢性丙型肝炎感染
J Clin Exp Hepatol. 2020 May-Jun;10(3):189-193. doi: 10.1016/j.jceh.2019.10.004. Epub 2019 Nov 6.
4
The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment.索磷布韦与达卡他韦联合治疗方案对伴有严重肾功能损害的丙型肝炎患者安全有效。
J Gastroenterol Hepatol. 2020 Sep;35(9):1590-1594. doi: 10.1111/jgh.14994. Epub 2020 Feb 5.
5
Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis.基于索磷布韦的方案对 4-5 期慢性肾脏病合并丙型肝炎感染患者安全且有效：系统评价和荟萃分析。
Virol J. 2019 Mar 14;16(1):34. doi: 10.1186/s12985-019-1140-x.
6
Burden of hepatitis C virus infection in India: A systematic review and meta-analysis.印度丙型肝炎病毒感染负担：系统评价和荟萃分析。
J Gastroenterol Hepatol. 2019 Feb;34(2):321-329. doi: 10.1111/jgh.14466. Epub 2018 Sep 26.
7
Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.达卡他韦与低剂量索磷布韦：一种用于估算肾小球滤过率<30 mL/min的丙型肝炎患者的有效泛基因型治疗方案。
Nephrology (Carlton). 2019 Mar;24(3):316-321. doi: 10.1111/nep.13222.
8
Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis.聚乙二醇化干扰素和利巴韦林应答导向疗法对维持性透析的慢性丙型肝炎病毒感染患者的安全性和有效性
Nephrology (Carlton). 2017 Sep;22(9):706-711. doi: 10.1111/nep.12833.

Rescue use of Pegylated Interferon in Dialysis Patient who Failed to Respond Sofosbuvir.

作者信息

Katiyar Harshita, Tiwari Prachi, Bhadauria Dharmendra S, Rai Praveer, Goel Amit

机构信息

Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.

Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.

出版信息

Indian J Nephrol. 2023 Mar-Apr;33(2):152-154. doi: 10.4103/ijn.IJN_259_21. Epub 2023 Feb 20.

DOI:10.4103/ijn.IJN_259_21
PMID:37234437
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10208530/
Abstract
摘要